NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

NewAmsterdam Pharma (Nasdaq: NAMS) announced inducement grants of options covering 217,000 ordinary shares to four non-executive new hires under its 2024 Inducement Plan pursuant to Nasdaq Listing Rule 5635(c)(4).

The options carry an exercise price of $31.57 (closing price on Feb 2, 2026) and vest over four years: 25% after one year, then 36 equal monthly installments, subject to continued service and plan terms.

AI-generated analysis. Not financial advice.

News Market Reaction – NAMSW

+10.78%

1 alert

+10.78% News Effect

On the day this news was published, NAMSW gained 10.78%, reflecting a significant positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

NAARDEN, The Netherlands and MIAMI, Feb. 06, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam’s Board of Directors approved the grant of inducement share options covering an aggregate of 217,000 of NewAmsterdam’s ordinary shares to four (4) non-executive new hires. The share options were granted as an inducement material to the employees’ acceptance of employment with NewAmsterdam pursuant to the NewAmsterdam Pharma Company N.V. 2024 Inducement Plan (the “2024 Inducement Plan”) and in accordance with Nasdaq Listing Rule 5635(c)(4).

The share options have an exercise price per share equal to $31.57, which represents the closing market price on the Nasdaq Stock Market of the Company’s ordinary shares on February 2, 2026, the grant date. The shares subject to the options will vest over four years, with 25% of the shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the shares vesting in a series of 36 equal monthly installments thereafter, subject to each employee’s continued service with NewAmsterdam on such vesting dates. The options are subject to the terms and conditions of the 2024 Inducement Plan and the terms and conditions of an option award agreement covering the grant.

About NewAmsterdam
NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 studies, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated.

Company Contact
Matthew Philippe
P: 1-917-882-7512
matthew.philippe@newamsterdampharma.com

FAQ

What did NewAmsterdam (NAMS) announce about inducement option grants on February 6, 2026?

They granted inducement options covering 217,000 ordinary shares to four non-executive hires. According to the company, the grants were made under the 2024 Inducement Plan and comply with Nasdaq Listing Rule 5635(c)(4).

What is the exercise price and grant date for the NAMS inducement options?

The exercise price is $31.57 per share, reflecting the closing Nasdaq price on Feb 2, 2026. According to the company, that closing price was used to set the exercise price for the grant date.

How do the NAMS inducement options vest for the new hires?

Options vest over four years: 25% at one year, then 36 equal monthly installments thereafter. According to the company, vesting is conditioned on each employee's continued service through the vesting dates.

Under which plan and Nasdaq rule were the NewAmsterdam (NAMS) inducement options granted?

The grants were made under the 2024 Inducement Plan and pursuant to Nasdaq Listing Rule 5635(c)(4). According to the company, this rule permits inducement awards for new employees outside existing equity plans.

How many employees received inducement option grants from NewAmsterdam (NAMS)?

Four non-executive new hires received option grants covering an aggregate of 217,000 shares. According to the company, the awards were material to those employees' acceptance of employment.